Skip to main content

Venker Eric's Form 4 filing

Roivant Sciences Ltd. (ROIV) · filed Nov 22, 2024

Accession no.
0001140361-24-047697
Filed
Nov 22, 2024
Trade date
Nov 20, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.13M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Venker EricCIK 0001801917Officer (President & COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 20, 2024Common SharesFTax withholdingDisposed−10,945$11.49−$125,758.05606,525Direct
Nov 20, 2024Common SharesMOption exerciseAcquired+100,000$3.85+$385,000706,525Direct
Nov 20, 2024Common SharesSSaleDisposed−100,000$11.32F2−$1,132,000606,525Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 20, 2024Common StockMOption exerciseDisposed−100,000$0.00$012,326,234Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)